Wybór sposobu leczenia nadciśnienia tętniczego u pacjenta z towarzyszącymi czynnikami ryzyka i zespołem metabolicznym Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2017
Słowa kluczowe:
nadciśnienie tętnicze, zespół metaboliczny, perindopril, indapamid
##plugins.themes.bootstrap3.article.main##
Abstrakt
W codziennej praktyce klinicznej leczenie nadciśnienia tętniczego u pacjentów z zaburzeniami metabolicznymi (zespołem metabolicznym i/lub cukrzycą) stanowi ogromne wyzwanie. Jest to spowodowane zarówno koniecznością osiągnięcia niskich, docelowych wartości ciśnienia tętniczego, jak i koniecznością redukcji ryzyka sercowo-naczyniowego i poprawy profilu metabolicznego. Wybór sposobu farmakoterapii hipotensyjnej w tej grupie wymaga znajomości najnowszej wiedzy naukowej i stosowania substancji o udowodnionym korzystnym wpływie na metabolizm, takich jak perindopril i indapamid, którym poświęcono poniższe opracowanie.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Płatek , A. E., & Szymański , F. M. (2017). Wybór sposobu leczenia nadciśnienia tętniczego u pacjenta z towarzyszącymi czynnikami ryzyka i zespołem metabolicznym. Medycyna Faktów , 10(3(36), 251-257. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2134
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Ali M.K., Bullard K.M., Saaddine J.B. et al.: Achievement of goals in U.S. diabetes care, 1999-2010. N. Engl. J. Med. 2013; 368: 1613-1624.
2. Buse J.B., Ginsberg H.N., Bakris G.L. et al.; American Heart Association; American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162-172.
3. Gaede P., Lund-Andersen H., Parving H.-H., Pedersen O.: Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008; 358: 580-591.
4. Grundy S.M.: Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 2007; 92: 399-404.
5. Grundy S.M., Cleeman J.I., Daniels S.R. et al.; American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
6. Grundy S.M.: Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 629-636.
7. Alberti K.G., Eckel R.H., Grundy S.M. et al.: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
9. Gurgenian S.V., Vatinian S.K., Zelveian P.A.: Arterial hypertension in metabolic syndrome: pathophysiological aspects. Ter. Arkh. 2014; 86(8): 128-132.
10. American Diabetes Association: Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin. Diabetes. 2016; 34(1): 3-21.
11. 2017 Guidelines on the management of diabetic patients: A position of Diabetes Poland. Clin. Diabet. 2017; 6(supl. A): A1-A80.
12. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertension 2015; 19: 53-58.
13. Lackland D.T., Voeks J.H.: Metabolic syndrome and hypertension: regular exercise as part of lifestyle management. Curr. Hypertens. Rep. 2014; 16(11): 492.
14. Patel A., ADVANCE Collaborative Group; MacMahon S., Chalmers J., Neal B. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
15. Zoungas S., Chalmers J., Neal B. et al.; ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371(15): 1392-1406.
16. Farsang C.; Picasso Investigators: Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. Blood Press. 2013; 22: supl. 1: 3-10.
17. Askerov M.M.: Hypotensive and metabolic effect of indapamide and perindopril in patients with type 2 diabetes and arterial hypertensia. Georgian Med. News 2009; (169): 44-48.
18. Semenkin A.A., Zhenatov A.B., Zhivilova L.A. et al.: Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or hydrochlorothiazide. Kardiologiia 2014; 54(11): 25-29.
19. Karpov Y.A.; FORTISSIMO physicians: Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study. Clin Drug Investig. 2017; 37(2): 207-217.
20. Glezer M.G.; On Behalf Of The Forsage Program Participants: Adherence of Patients to Antihypertensive Therapy With Combination of Perindopril and Indapamide According to Data of the FORSAGE Program. Kardiologiia 2017; 57(4): 33-37.
21. Lauffenburger J.C., Landon J.E., Fischer M.A.: Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study. J. Gen. Intern. Med. 2017; 32(6): 619-625.
22. Baroletti S., Dell’Orfano H.: Medication Adherence in Cardiovascular Disease. Circulation 2010; 121: 1455-1458.
2. Buse J.B., Ginsberg H.N., Bakris G.L. et al.; American Heart Association; American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162-172.
3. Gaede P., Lund-Andersen H., Parving H.-H., Pedersen O.: Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008; 358: 580-591.
4. Grundy S.M.: Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 2007; 92: 399-404.
5. Grundy S.M., Cleeman J.I., Daniels S.R. et al.; American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
6. Grundy S.M.: Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 629-636.
7. Alberti K.G., Eckel R.H., Grundy S.M. et al.: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
9. Gurgenian S.V., Vatinian S.K., Zelveian P.A.: Arterial hypertension in metabolic syndrome: pathophysiological aspects. Ter. Arkh. 2014; 86(8): 128-132.
10. American Diabetes Association: Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin. Diabetes. 2016; 34(1): 3-21.
11. 2017 Guidelines on the management of diabetic patients: A position of Diabetes Poland. Clin. Diabet. 2017; 6(supl. A): A1-A80.
12. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertension 2015; 19: 53-58.
13. Lackland D.T., Voeks J.H.: Metabolic syndrome and hypertension: regular exercise as part of lifestyle management. Curr. Hypertens. Rep. 2014; 16(11): 492.
14. Patel A., ADVANCE Collaborative Group; MacMahon S., Chalmers J., Neal B. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
15. Zoungas S., Chalmers J., Neal B. et al.; ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371(15): 1392-1406.
16. Farsang C.; Picasso Investigators: Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. Blood Press. 2013; 22: supl. 1: 3-10.
17. Askerov M.M.: Hypotensive and metabolic effect of indapamide and perindopril in patients with type 2 diabetes and arterial hypertensia. Georgian Med. News 2009; (169): 44-48.
18. Semenkin A.A., Zhenatov A.B., Zhivilova L.A. et al.: Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or hydrochlorothiazide. Kardiologiia 2014; 54(11): 25-29.
19. Karpov Y.A.; FORTISSIMO physicians: Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study. Clin Drug Investig. 2017; 37(2): 207-217.
20. Glezer M.G.; On Behalf Of The Forsage Program Participants: Adherence of Patients to Antihypertensive Therapy With Combination of Perindopril and Indapamide According to Data of the FORSAGE Program. Kardiologiia 2017; 57(4): 33-37.
21. Lauffenburger J.C., Landon J.E., Fischer M.A.: Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study. J. Gen. Intern. Med. 2017; 32(6): 619-625.
22. Baroletti S., Dell’Orfano H.: Medication Adherence in Cardiovascular Disease. Circulation 2010; 121: 1455-1458.